ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Levine, Mendelsohn Win Landon Awards; Ullrich Wins Pezcoller.

February 29, 2008

Elizabeth Miller Will Be Named to Cancer Panel

June 17, 1977

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Researchers Uncover Tumors Sensitive to Chemotherapy

January 25, 2013

In Brief: After Nickles Removes Block, Senate Confirms Oncologist Henney As FDA Commissioner

October 23, 1998

In Brief: NASA Procurement Specialist Names NEW NCI Contracts Chief; NIH Delays CREG Approval

January 3, 1975